Source:http://linkedlifedata.com/resource/pubmed/id/16113755
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2005-8-22
|
pubmed:abstractText |
Proteolytic factors belonging t the plasminogen activator family (plasmin, u-PA, t-PA, u-PAR, PAI-1, and PAI-2), which usually are involved in blood clotting and degradation of blood clots, are also present in healthy and diseased tissue of the kidney, lung, liver, gastro-intestinal tract, breast, prostate, ovary, and brain. These factors are engaged in brain development, angiogenesis and vascular invasion, wound healing as well as in placenta development and embryogenesis. Plasminogen activators u-PA and t-PA, their inhibitors PAI-1 and PAI-2, and the u-PA-receptor (u-PAR, CD87) are often elevated in solid malignant tumour tissues compared to their normal counterparts. In breast cancer patients, an elevated tumour tissue extract antigen content of u-PA, PAI-1, and u-PAR is associated with increased tumour aggressiveness and poor prognosis; in contrary, an elevated content of t-PA and PAI-2 indicates a favourable prognosis. For clinical relevant determination of these proteolytic factors in tumour tissue extracts, only enzymo-immunometric tests (ELISA) are recommended. Enzymometric and enzymographic tests are actually conducted only in an experimental, preclinical context.
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 2,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0720-9355
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
301-10
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:16113755-Biological Markers,
pubmed-meshheading:16113755-Humans,
pubmed-meshheading:16113755-Neoplasms,
pubmed-meshheading:16113755-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:16113755-Plasminogen Activator Inhibitor 2,
pubmed-meshheading:16113755-Plasminogen Activators,
pubmed-meshheading:16113755-Prognosis,
pubmed-meshheading:16113755-Reference Values,
pubmed-meshheading:16113755-Tissue Plasminogen Activator,
pubmed-meshheading:16113755-Urokinase-Type Plasminogen Activator
|
pubmed:year |
2005
|
pubmed:articleTitle |
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
|
pubmed:affiliation |
Klinische Forschergruppe, Frauenklinik der Technischen Universität München, Ismaninger Str. 22, 81675 München.
|
pubmed:publicationType |
Journal Article,
English Abstract
|